Inhibition of the NLRP3 inflammasome using MCC950 reduces vincristine‐induced adverse effects in an acute lymphoblastic leukemia patient‐derived xenograft model
Hana Starobova(The University of Queensland), Irina Vetter(Centre National de la Recherche Scientifique), Christopher M. Smith(University Hospital Coventry), Svetlana Shatunova(The University of Queensland), Ingrid G. Winkler(Translational Research Institute), Hannah McCalmont(Cancer Institute of New South Wales), Avril A. B. Robertson(The University of Queensland), Nicolette Tay(The University of Queensland), Richard B. Lock(Cancer Institute of New South Wales)
Cited by 4
Related Papers
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
|Nature Medicine|2015|2.8k
Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
|Science|2017|1.5k
Methods Used to Evaluate Pain Behaviors in Rodents
|Frontiers in Molecular Neuroscience|2017|1.3k
Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy
|Frontiers in Molecular Neuroscience|2017|654
The pediatric preclinical testing program: Description of models and early testing results
|Pediatric Blood & Cancer|2006|486